Gland Pharma shares surged over 13% on November 5, driven by strong Q2 earnings that, according to analysts, may indicate an end to the company’s recent struggles.
As of 12:54 PM, Gland Pharma shares were trading at ₹1,803 on the NSE. The stock’s modest performance this year has lagged behind the Nifty Pharma index, which gained 50%. However, analysts at Kotak Institutional Equities (KIE) believe the downside risk for Gland Pharma is now limited, upgrading the stock to an ‘add’ rating from its previous ‘reduce’ recommendation and raising the price target by over 11% to ₹1,625.
While Gland Pharma’s Q2 net profit dropped 16% year-on-year to ₹163.5 crore on a 2% rise in revenue to ₹1,406 crore, the management remains optimistic about the future. “Our core regulated markets, particularly in the United States, are performing well. We are focused on new markets and building a foundation for future growth,” stated Srinivas Sadu, Executive Chairman and CEO of Gland Pharma.
During Q2, Gland Pharma signed an agreement with Dr. Reddy’s Laboratories for a strategic partnership in biologics contract development and manufacturing (CDMO). This collaboration will utilize Gland Pharma’s advanced biologics facility in Hyderabad, with both companies expecting significant value from this partnership.
In contrast, Goldman Sachs remains cautious, noting that growth in Gland’s US business could pressure margins. It maintains a ‘sell’ rating on the stock with a price target of ₹1,450.
Do you have a news tip for Lakshmishree reporters? Please email us at media@lakshmishree.com
Source: Moneycontrol
News Desk
